Aurealis Therapeutics Overview
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Series B
- (Upcoming)
- Latest Deal Amount
-
$40.9M
- Investors
-
11
Aurealis Therapeutics General Information
Description
Developer of a cell and gene therapy platform designed to heal multifactorial diseases. The company's platform facilitates a novel class of combination immunotherapy embedded in a single product that is efficient, scalable, and cost-effective, enabling medical professionals to get access to activate and modulate the innate immune system.
Contact Information
Website
www.aurealistherapeutics.comCorporate Office
- Baarerstrasse 21
- 6300 Zug
- Switzerland
Corporate Office
- Baarerstrasse 21
- 6300 Zug
- Switzerland
Aurealis Therapeutics Timeline
Aurealis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC (Series B) | $40.9M | Upcoming | Clinical Trials - Phase 2 | |||
| 13. Later Stage VC | 15-Nov-2024 | Completed | Clinical Trials - Phase 2 | |||
| 12. Later Stage VC (Series A) | 30-Mar-2023 | Completed | Clinical Trials - Phase 2 | |||
| 11. Later Stage VC | 01-Nov-2022 | Completed | Clinical Trials - Phase 2 | |||
| 10. Secondary Transaction - Private | 01-Jan-2022 | Completed | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC | 14-Jun-2021 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC | 21-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 05-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC | 08-Feb-2019 | $7.85M | $18M | Completed | Pre-Clinical Trials | |
| 5. Later Stage VC | 24-May-2017 | $5.66M | $10.1M | Completed | Pre-Clinical Trials |
Aurealis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 104,800 | $0.111261 | $13.35 | $13.35 | 1x | $13.35 | 3.46% | |
| Ordinary | 357,814 | $0.111261 | $8.29 | $8.29 | 1x | $8.29 | 11.83% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Aurealis Therapeutics Comparisons
Industry
Financing
Details
Aurealis Therapeutics Competitors (65)
One of Aurealis Therapeutics’s 65 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Ambrx | Formerly PE-Backed | San Diego, CA | ||||
| Amphivena Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Aurealis Therapeutics Patents
Aurealis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019433065-A1 | Chloride-inducible prokaryotic expression system | Active | 04-Mar-2019 | ||
| AU-2019433065-B2 | Chloride-inducible prokaryotic expression system | Active | 04-Mar-2019 | ||
| CA-3131796-A1 | Chloride-inducible prokaryotic expression system | Active | 04-Mar-2019 | ||
| CA-3131796-C | Chloride-inducible prokaryotic expression system | Active | 04-Mar-2019 | ||
| EP-3921422-A1 | Chloride-inducible prokaryotic expression system | Active | 04-Mar-2019 | C12N15/746 |
Aurealis Therapeutics Signals
Aurealis Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lynx Financial | Venture Capital | Minority | ||
| Zhejiang Huahai Pharmaceutical | Corporation | Minority | ||
| Founders' Edge | Venture Capital | Minority | ||
| Tesi | Limited Partner | Minority | ||
| Connecticut Innovations | Venture Capital | Minority |
Aurealis Therapeutics FAQs
-
Where is Aurealis Therapeutics headquartered?
Aurealis Therapeutics is headquartered in Zug, Switzerland.
-
What is the size of Aurealis Therapeutics?
Aurealis Therapeutics has 18 total employees.
-
What industry is Aurealis Therapeutics in?
Aurealis Therapeutics’s primary industry is Drug Discovery.
-
Is Aurealis Therapeutics a private or public company?
Aurealis Therapeutics is a Private company.
-
What is Aurealis Therapeutics’s current revenue?
The current revenue for Aurealis Therapeutics is .
-
How much funding has Aurealis Therapeutics raised over time?
Aurealis Therapeutics has raised $40.3M.
-
Who are Aurealis Therapeutics’s investors?
Lynx Financial, Zhejiang Huahai Pharmaceutical, Founders' Edge, Tesi, and Connecticut Innovations are 5 of 11 investors who have invested in Aurealis Therapeutics.
-
Who are Aurealis Therapeutics’s competitors?
CytomX Therapeutics, Carisma Therapeutics, Ambrx, Amphivena Therapeutics, and Adaptimmune Therapeutics are some of the 65 competitors of Aurealis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process